Williams S. Ettouati, PharmD, MA
Executive Advisor, Graduate Programs, Office of the Vice Chancellor of Health Sciences, UC San Diego | Managing Director, Master of Advanced Studies in Precision Medicine Therapeutics in Oncology, School of Medicine | Managing Director, Master of Science in Drug Development & Product Management, Skaggs School of Pharmacy & Pharmaceutical Sciences | Health Sciences Associate Clinical Professor, N.S.
- Profile
Profile
Dr. Ettouati is currently an Executive Advisor for the Graduate Programs in the Office of the Vice Chancellor Health Sciences for UC San Diego. In addition, he is Managing Director for the Master of Science in Drug Development & Product Management program at the Skaggs School of Pharmacy & Pharmaceutical Sciences and Managing Director for the Master of Advanced Studies in Precision Medicine Therapeutics in Oncology program at UC San Diego, School of Medicine. Dr. Ettouati's role in the MAS in PMTO program is to manage program operations and teach a two-unit course in drug commercialization in the era of precision medicine therapeutics.
Before joining UC San Diego, Dr. Ettouati spent twenty years in the pharmaceutical and biotechnology industry in senior leadership roles (e.g., CEO, President &Co-Founder, Director, Chief Business Officer). Dr. Ettouati has proven and extensive experience encompassing multiple functional disciplines in pharmaceutical and biotechnology executive management, in areas such as business development, licensing, marketing and new product planning strategy in biotech and pharmaceutical companies.
Before joining UC San Diego, Dr. Ettouati spent twenty years in the pharmaceutical and biotechnology industry in senior leadership roles (e.g., CEO, President &Co-Founder, Director, Chief Business Officer). Dr. Ettouati has proven and extensive experience encompassing multiple functional disciplines in pharmaceutical and biotechnology executive management, in areas such as business development, licensing, marketing and new product planning strategy in biotech and pharmaceutical companies.